{"id":70412,"date":"2026-07-22T13:32:59","date_gmt":"2026-07-22T05:32:59","guid":{"rendered":"https:\/\/flcube.com\/?p=70412"},"modified":"2026-07-22T13:33:00","modified_gmt":"2026-07-22T05:33:00","slug":"trinomab-biotechnology-debuts-on-shanghai-star-market-with-first-in-class-anti-tetanus-monoclonal-antibody","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70412","title":{"rendered":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Trinomab Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688806:SHA\">SHA: 688806<\/a>) officially listed on the <strong>Science and Technology Innovation Board<\/strong> (STAR Market) of the <strong>Shanghai Stock Exchange<\/strong> under stock code <strong>688806<\/strong>. Founded in <strong>2015<\/strong>, the company is pioneering <strong>alternative therapies for plasma-derived products<\/strong> through innovative monoclonal antibody development.<\/p>\n\n\n\n<h2 id=\"h-ipo-details\" class=\"wp-block-heading\">IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Shanghai Stock Exchange \u2013 STAR Market<\/td><\/tr><tr><td><strong>Stock Code<\/strong><\/td><td>688806<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>July 21, 2026<\/td><\/tr><tr><td><strong>Company Focus<\/strong><\/td><td>Alternative therapies to plasma-derived products<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2015<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-portfolio-amp-pipeline\" class=\"wp-block-heading\">Product Portfolio &amp; Pipeline<\/h2>\n\n\n\n<h3 id=\"h-siltartoxatug-commercialized-asset\" class=\"wp-block-heading\">Siltartoxatug \u2013 Commercialized Asset<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Status:<\/strong> <strong>Approved for marketing<\/strong> by China&#8217;s <strong>National Medical Products Administration<\/strong> (NMPA)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>World&#8217;s first-in-class fully human anti-tetanus monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Significance:<\/strong> Represents a <strong>plasma-free alternative<\/strong> to traditional tetanus immunoglobulin derived from human plasma<\/li>\n\n\n\n<li><strong>Commercial Stage:<\/strong> First commercialized core product generating revenue<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-tnm001-late-stage-pipeline-candidate\" class=\"wp-block-heading\">TNM001 \u2013 Late-Stage Pipeline Candidate<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Status:<\/strong> <strong>New Drug Application<\/strong> (NDA) submitted with <strong>Priority Review status<\/strong> granted in China<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Respiratory syncytial virus<\/strong> (RSV)<\/li>\n\n\n\n<li><strong>Technology:<\/strong> <strong>Recombinant long-acting fully human monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Awaiting regulatory decision following priority review designation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-differentiation\" class=\"wp-block-heading\">Strategic Differentiation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Trinomab&#8217;s platform addresses critical limitations of <strong>plasma-derived therapies<\/strong>, which face challenges including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supply constraints<\/strong> due to dependence on human plasma donations<\/li>\n\n\n\n<li><strong>Batch-to-batch variability<\/strong> in product quality<\/li>\n\n\n\n<li><strong>Risk of blood-borne pathogen transmission<\/strong><\/li>\n\n\n\n<li><strong>Limited scalability<\/strong> for global distribution<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s <strong>fully human monoclonal antibody approach<\/strong> offers consistent quality, scalable manufacturing, and enhanced safety profiles compared to traditional plasma-derived alternatives.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity\" class=\"wp-block-heading\">Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The global market for <strong>tetanus prophylaxis<\/strong> and <strong>RSV therapeutics<\/strong> represents significant commercial potential:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tetanus:<\/strong> Annual global demand for tetanus immunoglobulin exceeds <strong>1 million doses<\/strong><\/li>\n\n\n\n<li><strong>RSV:<\/strong> Affects approximately <strong>33 million children annually<\/strong> worldwide, with limited treatment options<\/li>\n\n\n\n<li><strong>Plasma Alternatives:<\/strong> Growing regulatory and clinical preference for recombinant over plasma-derived products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-thesis\" class=\"wp-block-heading\">Investment Thesis<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Trinomab&#8217;s dual-pronged strategy combines <strong>near-term revenue generation<\/strong> from its approved anti-tetanus antibody with <strong>high-value pipeline potential<\/strong> in the RSV therapeutic market. The company&#8217;s focus on <strong>first-in-class monoclonal antibodies<\/strong> positions it as a leader in the plasma-alternative therapeutic category.<\/p>\n\n\n\n<h2 id=\"h-company-background\" class=\"wp-block-heading\">Company Background<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Since its founding in 2015, Trinomab has built a specialized expertise in <strong>monoclonal antibody development<\/strong> targeting infectious disease indications traditionally addressed with plasma-derived products. The company&#8217;s listing on the STAR Market provides capital to accelerate commercialization and advance its pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and market opportunities. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70413,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[72,4867,1848],"class_list":["post-70412","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-sha-688806","tag-trinomab-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody\" \/>\n<meta property=\"og:description\" content=\"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T05:32:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T05:33:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody\",\"datePublished\":\"2026-07-22T05:32:59+00:00\",\"dateModified\":\"2026-07-22T05:33:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2202.webp\",\"keywords\":[\"IPO\",\"SHA: 688806\",\"Trinomab Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70412#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70412\",\"name\":\"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2202.webp\",\"datePublished\":\"2026-07-22T05:32:59+00:00\",\"dateModified\":\"2026-07-22T05:33:00+00:00\",\"description\":\"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70412\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody - Insight, China&#039;s Pharmaceutical Industry","description":"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70412","og_locale":"en_US","og_type":"article","og_title":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody","og_description":"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.","og_url":"https:\/\/flcube.com\/?p=70412","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-22T05:32:59+00:00","article_modified_time":"2026-07-22T05:33:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody","datePublished":"2026-07-22T05:32:59+00:00","dateModified":"2026-07-22T05:33:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70412"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","keywords":["IPO","SHA: 688806","Trinomab Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70412#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70412","url":"https:\/\/flcube.com\/?p=70412","name":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70412#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","datePublished":"2026-07-22T05:32:59+00:00","dateModified":"2026-07-22T05:33:00+00:00","description":"Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70412"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70412#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","width":1080,"height":608,"caption":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70412\/revisions"}],"predecessor-version":[{"id":70414,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70412\/revisions\/70414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70413"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}